Global Biopharmaceutical CDMO Market Insights, Forecast to 2030

Global Biopharmaceutical CDMO Market Insights, Forecast to 2030

The global Biopharmaceutical CDMO market is projected to grow from US$ 28.16 billion in 2024 to US$ 59.05 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 13.14% during the forecast period.

Report Includes

This report presents an overview of global market for Biopharmaceutical CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Biopharmaceutical CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biopharmaceutical CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biopharmaceutical CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biopharmaceutical CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biopharmaceutical CDMO revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, and AGC Biologics, etc.

Market Segmentation

By Company

Lonza

Catalent

Samsung Biologics

FUJIFILM Diosynth Biotechnologies

Boehringer Ingelheim

WuXi AppTech

Recipharm

Thermo Fisher Scientific

AGC Biologics

Rentschler Biopharma

KBI Biopharma

Siegfried

Aenova Group

GenScript

ProBioGen

Northway Biotech

3P Biopharmaceuticals

Segment by Type

Cell and Gene Therapies

Antibodies

Vaccines

Other

Segment by Application

SMBs

Large Companies

By Region

North America

United States

Canada

Mexico

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of APAC

Europe

Germany

France

U.K.

Italy

Russia

Rest of Europe

Latin America

Brazil

Argentina

Colombia

Rest of Latin America

Middle East & Africa

Middle East

Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Biopharmaceutical CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biopharmaceutical CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: Asia-Pacific by Type, and by Application, revenue for each segment.

Chapter 9: Latin America by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biopharmaceutical CDMO revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions